A carregar...
Hematologic toxicity of concurrent administration of Radium-223 and next generation anti-androgen therapies
PURPOSE/OBJECTIVES: Radium-223 is a first-in-class radiopharmaceutical recently approved for the treatment of castration-resistant prostate cancer (CRPC) in patients with symptomatic bone metastases. Initial studies investigating Radium-223 primarily utilized non-steroidal first-generation anti-andr...
Na minha lista:
Publicado no: | Am J Clin Oncol |
---|---|
Main Authors: | , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4549230/ https://ncbi.nlm.nih.gov/pubmed/25723740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000181 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|